Close

Top stories

Market Access/ News/ News/ Top stories

Ahead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dips

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, fda, Moderna, Pfizer 0 Comment

Pfizer and Moderna have both reported data that they say backs up the need for booster shots of

X

Ahead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dips

https://pharmaphorum.com/news/ahead-of-fda-adcomm-pfizer-moderna-say-covid-jab-efficacy-dips/

Vaccine vial dose flu shot drug needle syringe,medical concept vaccination hypodermic injection treatment disease care hospital prevention immunization illness disease baby child.blue background

News/ News/ Sales and Marketing/ Top stories

EU ‘negotiating with Valneva’ over COVID-19 vaccine contract

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, MHRA, UK, Valneva 0 Comment

The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to

X

EU ‘negotiating with Valneva’ over COVID-19 vaccine contract

https://pharmaphorum.com/news/eu-negotiating-with-valneva-over-covid-19-vaccine-contract/

News/ News/ Patients/ Top stories

Astellas reports fourth death in halted gene therapy trial

Phil Taylor Astellas, gene therapy, patients, rare disease, safety 0 Comment

There has been a fourth patient fatality in Astellas’ clinical trial of its AT132 gene therapy for the

X

Astellas reports fourth death in halted gene therapy trial

https://pharmaphorum.com/news/astellas-reports-fourth-death-in-halted-gene-therapy-trial/

News/ News/ Oncology/ Top stories

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

Phil Taylor BeiGene, fda, immuno-oncology, Novartis, oesophageal cancer, Oncology 0 Comment

Novartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier

X

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

https://pharmaphorum.com/news/first-fda-filing-for-novartis-latecomer-pd-1-drug-tislelizumab/

News/ News/ Patients/ Top stories

NHS England starts largest ever trial of Galleri cancer blood test

Phil Taylor cancer screening, diagnostic, Galleri, Grail, Illumina, liquid biopsy, NHS, NHS England, Oncology 0 Comment

A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will

X

NHS England starts largest ever trial of Galleri cancer blood test

https://pharmaphorum.com/news/nhs-england-starts-largest-ever-trial-of-galleri-cancer-blood-test/

News/ News/ R&D/ Top stories

Cheap gout drug colchicine added to UK’s RECOVERY COVID-19 trial

Richard Staines colchicine, coronavirus, COVID-19, R&D, RECOVERY 0 Comment

Colchicine, a cheap and readily available anti-inflammatory drug used to treat diseases such as gout, is to be

X

Cheap gout drug colchicine added to UK’s RECOVERY COVID-19 trial

https://pharmaphorum.com/news/colchicine-added-to-uks-ground-breaking-recovery-covid-19-trial/

Market Access/ News/ News/ Top stories

EU fines Teva and Cephalon €60.5m for ‘pay for delay’ scheme

Richard Staines Cephalon, generic, litigation, modafinil, patent, Teva 0 Comment

The European Union has fined Teva and its neurology unit Cephalon €60.5 million for an elaborate “pay for

X

EU fines Teva and Cephalon €60.5m for ‘pay for delay’ scheme

https://pharmaphorum.com/news/eu-fines-teva-and-cephalon-e60-5m-for-pay-for-delay-scheme/

News/ News/ R&D/ Top stories

Concerns emerge after AZ’s lucky vaccine trial ‘mistake’

Richard Staines AstraZeneca, AZD-1222, coronavirus, COVID-19, Moderna, Pfizer, R&D 0 Comment

AstraZeneca may have tried a positive spin on the trial mistake that led to the accidental discovery of

X

Concerns emerge after AZ’s lucky vaccine trial ‘mistake’

https://pharmaphorum.com/news/concerns-emerge-after-azs-vaccine/

News/ News/ R&D/ Top stories

Novartis set to overcome $14 billion patent cliff say analysts

Richard Staines biosimilars, cancer, inflammatory diseases, Novartis, pipeline, R&D, Sandoz 0 Comment

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition

X

Novartis set to overcome $14 billion patent cliff say analysts

https://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/

1 2 3 4 ›»

CONTINUE TO SITE >

X

Close in 10 seconds

Pharmaphorum.com

Trending

Top stories

Login